Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/44524
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDomen, Julie-
dc.contributor.authorABRAMS, Steven-
dc.contributor.authorDigregorio, Marina-
dc.contributor.authorVan Ngoc, Pauline-
dc.contributor.authorDuysburgh, Els-
dc.contributor.authorScholtes, Béatrice-
dc.contributor.authorCoenen , Samuel-
dc.date.accessioned2024-10-24T09:37:30Z-
dc.date.available2024-10-24T09:37:30Z-
dc.date.issued2024-
dc.date.submitted2024-10-23T18:05:15Z-
dc.identifier.citationBMC Infectious Diseases, 24 (1) (Art N° 135)-
dc.identifier.issn-
dc.identifier.urihttp://hdl.handle.net/1942/44524-
dc.description.abstractBackground COVID-19 vaccine effectiveness declines months after vaccination. Therefore, it is likely that during the next few years, people may be repeatedly offered a booster vaccine to enhance humoral immunity levels. A growing number of people are questioning whether the benefits of a booster vaccine outweigh the side-effects. Objective This study aims (1) to identify the most frequently reported side-effects after different doses of COVID-19 mRNA vaccines, (2) and the longest lasting symptoms; and (3) to predict the likelihood of having moderate-to-severe side-effects after a booster COVID-19 mRNA vaccine given individual-and vaccine-specific characteristics. Design, setting, and participants Secondary analysis of a prospective cohort study in primary health care providers (PHCPs) in Belgium conducted between December 2020 and December 2021, and in February-March 2023. Methods In nine subsequent surveys over a period of 2 years vaccine dose-number and side-effects after COVID-19 vaccines were collected. A Generalized Estimation Equations approach on the data of the first and second booster dose was used to investigate the probability of having moderate-to-severe side-effects after mRNA booster vaccination. Predictive performance of a binary classifier was assessed by looking at discrimination (i.e., quantified in terms of the area under the receiver operating characteristic curve). The final prediction model was validated using data with regard to the third booster by assessing misclassification rate, sensitivity and specificity. Results In total, 11% of the PHCPs had moderate-to-severe side-effects after their booster COVID-19 mRNA vaccine. The most common side-effects of COVID-19 mRNA doses included fatigue, local pain at the injection site, general pains, and headache. These side-effects typically lasted for a median of 1 to 2 days. The final model included five predictors: sex, alcohol consumption, history of moderate-to-severe side-effects after any previous dose, recent COVID-19 infection, and the booster dose-number (first, second). Having experienced moderate-to-severe side-
dc.description.sponsorshipThis work was supported by Sciensano (grant number OZ8478). Acknowledgements I acknowledge the dedicated participation of all healthcare providers who completed multiple surveys over two years. I also thank Sciensano for their collaboration in CHARMING, especially for making an extension possible for this purpose, and providing access to the LimeSurvey tool. Additionally, I am grateful to our colleagues at the University of Liège for their collaborative efforts in setting up the survey.-
dc.language.isoen-
dc.publisher-
dc.rightsThe Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by-nc-nd/4.0/.-
dc.subject.otherCOVID-19-
dc.subject.otherSARS-CoV-2 mRNA booster vaccine-
dc.subject.otherSide-effects-
dc.titlePredictors of moderate-to-severe side-effects following COVID-19 mRNA booster vaccination: a prospective cohort study among primary health care providers in Belgium-
dc.typeJournal Contribution-
dc.identifier.issue1-
dc.identifier.volume24-
local.bibliographicCitation.jcatA1-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.artnr135-
dc.identifier.doi10.1186/s12879-024-09969-8-
dc.identifier.isi001336898200005-
dc.identifier.eissn1471-2334-
local.provider.typePdf-
local.uhasselt.internationalno-
item.fulltextWith Fulltext-
item.contributorDomen, Julie-
item.contributorABRAMS, Steven-
item.contributorDigregorio, Marina-
item.contributorVan Ngoc, Pauline-
item.contributorDuysburgh, Els-
item.contributorScholtes, Béatrice-
item.contributorCoenen , Samuel-
item.fullcitationDomen, Julie; ABRAMS, Steven; Digregorio, Marina; Van Ngoc, Pauline; Duysburgh, Els; Scholtes, Béatrice & Coenen , Samuel (2024) Predictors of moderate-to-severe side-effects following COVID-19 mRNA booster vaccination: a prospective cohort study among primary health care providers in Belgium. In: BMC Infectious Diseases, 24 (1) (Art N° 135).-
item.accessRightsOpen Access-
crisitem.journal.eissn1471-2334-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
s12879-024-09969-8.pdfPublished version1.22 MBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.